Smith & Nephew’s (SN) “Sector Perform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Smith & Nephew (LON:SN) in a report released on Tuesday, MarketBeat.com reports. The firm currently has a GBX 1,350 target price on the stock.

Several other research analysts have also commented on SN. Berenberg Bank restated a “hold” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research note on Friday, January 23rd. Panmure Gordon reaffirmed a “hold” rating and issued a GBX 1,200 price objective on shares of Smith & Nephew in a research note on Tuesday, December 9th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Smith & Nephew presently has a consensus rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Stock Performance

Shares of SN opened at GBX 1,251.50 on Tuesday. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The company has a market capitalization of £13.72 billion, a price-to-earnings ratio of 45.06, a PEG ratio of 0.46 and a beta of 0.68. The company’s fifty day simple moving average is GBX 1,273.19 and its 200 day simple moving average is GBX 1,295.18.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.